Castrate Resistant Prostate Cancer Enhertu Therapy

Part of paid clinical trials in Washington D.C., District of Columbia.

Sponsor
Washington D.C. Veterans Affairs Medical Center
Study ID
NCT06610825
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Enhertu — DRUG
    This is an open label, multi-center, single arm, phase II study designed to investigate the anti-tumor activity, efficacy and safety of Enhertu in HER2-positive metastatic castrate-resistant prostate cancer patients who progressed on androgen deprivation therapy and novel hormonal agents (such as Abiraterone and Enzalutamide), who also progressed, refused, or were not candidates to receive taxane-based chemotherapy.

Study Details

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Key Dates

Start date
Mar 5, 2025
Status verified
Apr 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Enhertu for HER2 positive metastatic castrate resistant prostate cancer

Primary Outcome Measure

ORR [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Washington DC VAMCWashington D.C.District of Columbia20422
Asha Escobar
[email protected]
2027431090
Maneesh Jain, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Washington D.C., DC

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Washington DC VAMC· Washington D.C., DC

Related Studies